Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).
Note: this interview was filmed before the FDA approval of pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology
January 19th 2023“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
2 Clarke Drive
Cranbury, NJ 08512